Cell Therapy Treatments in Development

  • ALS

FDA-approved Phase II NSI-566/ALS clinical trial, expanded to three centers with significant increase in dosing, commenced in September 2013. In Mexico City, ALS Phase I / II trial expected to commence in 2014. More

  • Ischemic Stroke

NSI-566 Phase I / II trial for ischemic stroke commenced in December 2013, in collaboration with BaYi Brain Hospital in Beijing. More

  • Spinal Cord Injury

FDA approved Phase I safety trial transplanting NSI-566 into the T2-T12 lumbar regions of chronic SCI patients. University of California, San Diego IRB approval received and Phase I commencement expected in 2014. Acute SCI trial expected to commence in Seoul, South Korea in 2014.  More

  • Multiple Sclerosis

Preclinical phase with NSI-566. Further clinical development on multiple sclerosis application pending NSI-566 ALS ongoing trial.

  • Optic Neuritis

Preclinical phase with NSI-566. Further clinical development on optic neuritis application pending NSI-566 ALS ongoing trial.

Preclinical phase with NSI-566. Further clinical development on Alzheimer’s disease application pending NSI-566 ALS ongoing trial.

  • Traumatic Brain Injury

Preclinical phase with NSI-566. Further clinical development on traumatic brain injury application pending NSI-566 ALS ongoing trial.

  • Peripheral Nerve Injury

Preclinical phase with NSI-566. Further clinical development on peripheral nerve injury application pending NSI-566 ALS ongoing trial.

  • Diabetic Neuropathy

Preclinical phase with NSI-566. Further clinical development on diabetic neuropathy application pending NSI-566 ALS ongoing trial.

  • Lysosomal Diseases

Preclinical phase with NSI-566. Further clinical development on lysosomal diseases application pending NSI-566 ALS ongoing trial.

  • Parkinson’s Disease

Preclinical phase with NSI-566. Further clinical development on Parkinson’s disease application pending NSI-566 ALS ongoing trial.

  • Huntington’s Disease

Preclinical phase with NSI-566. Further clinical development on Huntington’s disease application pending NSI-566 ALS ongoing trial.

  • Cerebral Palsy

Preclinical phase with NSI-566. Further clinical development on cerebral palsy application pending NSI-566 ALS ongoing trial.

  • Ischemic Spastic Paraplegia

Preclinical phase with the University of California at San Diego. Lead collaborator, Dr. Martin Marsala, PhD authored a peer-reviewed paper on study results. More

Drug Treatments in Development

  • Major Depressive Disorder

Phase I trial for neurogenic small molecule drug, NSI-189, completed in 4Q13, with data showing clinically meaningful improvement across all depressive and cognitive measures. Phase II commencement expected in 2014. More

  • Alzheimer’s Disease

Preclinical phase with NSI-189, which was originally developed to address cognitive indications. Further clinical development on Alzheimer’s disease application pending NSI-189 major depressive disorder ongoing trial.

  • Cognitive complication due to Diabetes

Preclinical phase with NSI-189. Further clinical development on cognitive complication due to diabetes application pending NSI-189 major depressive disorder ongoing trial.

  • Stroke

Preclinical phase with NSI-189. Further clinical development on stroke application pending NSI-189 major depressive disorder ongoing trial.

  • Traumatic Brain Injury

Preclinical phase with NSI-189. Further clinical development on traumatic brain injury application pending NSI-189 major depressive disorder ongoing trial.

  • Post-Traumatic Stress Disorder

Preclinical phase with NSI-189. Further clinical development on PTSD application pending NSI-189 major depressive disorder ongoing trial.

  • Neurodegeneration

Preclinical phase with NSI-189. Further clinical development on neurodegeneration application pending NSI-189 major depressive disorder ongoing trial.

  • Anti-Aging (Nootropic)

Preclinical phase with NSI-189. Further clinical development on anti-aging (nootropic) application pending NSI-189 major depressive disorder ongoing trial.

Privacy and Terms ©Neuralstem, Inc. 2014